SMARCA2 and breast cancer: Combined knockdown of BRG1 and BRM has an additive effect on cell proliferation, while individual CRISPR/Cas9-mediated knockdown of BRG1 or BRM reduces cell viability, indicating that BRG1 and BRM have at least partially non-overlapping roles in promoting breast cancer cell proliferation [63].